Innovations and Challenges in Renal Cancer
Third Cambridge Conference
June 2008
Innovations and Challenges in Renal Cancer: Summary Statement from the Third Cambridge Conference
Michael B Atkins, MD, Ronald M Bukowski, MD, Bernard J Escudier, MD, Robert A Figlin, MD, Gary H Hudes, MD, William G Kaelin, Jr MD,W Marston Linehan, MD, David F McDermott, MD, James W Mier, MD, Ivan Pedrosa, MD, Brian I Rini, MD, Sabina Signoretti, MD, Jeffrey A Sosman, MD, Bin Tean Teh, MD, Christopher G Wood, MD, Amado J Zurita, MD, and Laura King
Hereditary Kidney Cancer: Unique Opportunity for Disease-Based Therapy
W. Marston Linehan, MD, Peter A. Pinto, MD, Gennady Bratslavsky, MD, Elizabeth Pfaffenroth, MD, Maria Merino, MD, Cathy D. Vocke, PhD, Jorge R. Toro, MD, Donald Bottaro, PhD, Len Neckers, PhD, Laura S. Schmidt, PhD, and Ramaprasad Srinivasan, MD, PhD
Treatment of Kidney Cancer: Insights provided by the VHL Tumor Suppressor Protein
William G. Kaelin, Jr., MD
Prognostic Factors for Survival in Metastatic Renal Cell Carcinoma: Update 2008
Ronald M. Bukowski, MD
The Complexity of Tumor Vasculature in Clear Cell Renal Cell Carcinoma
Chao-Nan Qian, MD, PhD, and Bin Tean Teh, MD, PhD
Tissue Biomarkers in Renal Cell Carcinoma: Issues and Solutions
Arianna Di Napoli, MD, and Sabina Signoretti, MD
Immunotherapy of Metastatic Renal Cell Carcinoma
David F. McDermott, MD
Vascular Endothelial Growth Factor–Targeted Therapy in Metastatic Renal Cell Carcinoma
Brian I. Rini, MD
Targeting mTOR and Other Components of the PI3K/Akt Pathway in Renal Carcinoma
Gary R. Hudes, MD
Sequential Therapy in Renal Cell Carcinoma
Bernard Escudier, MD, M. Gross Goupil, MD, C. Massard, MD, and K. Fizazi, MD, PhD
Treatment Selection for Patients With Metastatic Renal Cell Carcinoma
Michael B. Atkins, MD, Toni K. Choueiri, MD, Daniel Cho, MD, Meredith Regan, ScD, Sabina Signoretti, MD
Magnetic Resonance Imaging as a Biomarker in Renal Cell Carcinoma
Ivan Pedrosa, MD, David C. Alsop, PhD, Neil M. Rofsky, MD
Circulating Biomarkers for Vascular Endothelial Growth Factor Inhibitors in Renal Cell Carcinoma
Amado J. Zurita, MD, Eric Jonasch, MD, Hua-Kang Wu, PhD, Hai T. Tran, PharmD, John V. Heymach, MD, PhD
Neoadjuvant (Presurgical) Therapy for Renal Cell Carcinoma: A New Treatment Paradigm for Locally Advanced and Metastatic Disease
Christopher G. Wood, MD, and Vitaly Margulis, MD
Novel Therapeutics for Metastatic Renal Cell Carcinoma
Thomas E. Hutson, DO, PharmD, FACP, and Robert A. Figlin, MD, FACP
Combination Targeted Therapy in Advanced Renal Cell Carcinoma
Jeffrey Sosman, MD, and Igor Puzanov, MD
Mechanisms of Acquired Resistance to Vascular Endothelial Growth Factor Receptor Antagonists
David J. Panka, PhD, Manoj Kumar, PhD, Rupal Bhatt, MD, PhD, Rachel Schor-Bardach, MD, Liang Zhang, MD, S. Nahum Goldberg, MD, Towia Libermann, PhD, Michael B. Atkins, MD, and James W. Mier, MD
